Gene interactions and pathways from curated databases and text-mining

◀ Back to EGFR

EGFR — ERBB2

Pathways - manually collected, often from reviews:

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

Text-mined interactions from Literome

Chen et al., Biochem Biophys Res Commun 2000 (Breast Neoplasms) : Together, our results suggest that coexpression of EGFR or ErbB3 with ErbB2 induces high phosphorylation of ErbB2 and renders the cells more resistant to various anti-cancer drugs
Egeblad et al., Int J Cancer 2001 (Breast Neoplasms) : Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK independent loss of epithelial morphology
Bei et al., J Pathol 2001 (Carcinoma, Squamous Cell...) : Among invasive and in situ carcinoma, EGFR expression was the most prevalent ( in 29/32 and 8/11 cases, respectively ) followed by ErbB2 ( 17/32 and 2/11 ) and ErbB4 ( 9/32 and 1/10 ), while ErbB3 was only detected in invasive tumours ( 12/32 )
Feroz et al., Cell Signal 2002 : Thus, we hypothesized that ErbB2 enhances ligand induced ErbB family receptor signalling through mass action
Lin et al., Prostate 2003 : Because the pressor peptide Ang II signals through GPCRs, we tested the possibility that Ang II could transactivate ErbB1/ErbB2 in human prostate stromal ( hPS ) cells
Iivanainen et al., FASEB J 2003 : 3 ) Consistent with their known receptor specificities, recombinant HB-EGF, but not neuregulin-1, stimulated tyrosine phosphorylation of ErbB1 and ErbB2 and migration in SMCs. 4 ) Neutralization of HB-EGF or inhibition of ErbB1 or ErbB2 blocked 70-90 % of the potential of ECs to stimulate SMC migration
Gillgrass et al., Oncogene 2003 (Disease Progression...) : To directly assess whether the catalytic activity of EGFR is required for ErbB-2 induction of mammary tumors, we have interbred transgenic mice expressing ErbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus ( MMTV ) promoter/enhancer to a naturally occurring mouse mutant carrying a catalytically impaired EGFR ( waved-2 mice )
Kani et al., J Biol Chem 2005 : ErbB receptors associate in a ligand dependent or -independent manner, and overexpression of epidermal growth factor receptor ( ErbB1 ) or ErbB2 results in ligand independent activation
Haslekås et al., Mol Biol Cell 2005 : We have demonstrated that ErbB2 does not inhibit phosphorylation or ubiquitination of the EGFR
Yoon et al., Cancer Res 2006 (Breast Neoplasms...) : ErbB2 , a binding partner of epidermal growth factor receptor (EGFR), and EGFR modulated Ras activity, and integrin alpha(6)beta ( 4 ) regulated phospho-EGFR level without affecting EGFR expression
Beier et al., FEBS Lett 2006 : Activation of ErbB2 by 2-methyl-1,4-naphthoquinone ( menadione ) in human keratinocytes : role of EGFR and protein tyrosine phosphatases
Zandi et al., Cell Signal 2007 (Neoplasms) : Heterodimerization of EGFR with ErbB2 inhibits downregulation of EGFR and thereby prolongs growth factor signaling
Landau et al., Biochim Biophys Acta 2008 (Neoplasms) : That finding enabled us to elucidate, in molecular terms, the directionality observed in the activation process of ErbB heterodimers ; it can explain, for example, the preferential activation of ErbB2 by ErbB1 over activation of ErbB1 by ErbB2
Martin et al., Mol Pharmacol 2008 : Coexpression of dominant negative ERBB1 and dominant negative ERBB2 inhibited basal and EGF stimulated ERBB1 and ERBB2 phosphorylation in parental and adapted cells
Hughes et al., Mol Cancer Ther 2009 : Epidermal growth factor receptor (EGFR) and ErbB2 readily form heterodimers when both are expressed in the same cell and the EGFR is activated by one of its ligands
Lokeshwar et al., Cancer Res 2010 (Neoplasm Invasiveness...) : 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated IKB, phosphorylated ErbB2 , and phosphorylated epidermal growth factor receptor
Grassian et al., J Biol Chem 2011 : ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix detached cells
Li et al., J Biol Chem 2012 : Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization
Sak et al., Carcinogenesis 2013 (Breast Neoplasms) : Overexpression of ErbB2 has been demonstrated to inhibit epidermal growth factor induced internalization and degradation of epidermal growth factor receptor
Sasaoka et al., J Biol Chem 1996 : In Delta973-EGFR cells, ErbB2 was tyrosine phosphorylated in the basal state and EGFR stimulated further phosphorylation of ErbB2
Gulliford et al., Oncogene 1997 (Carcinoma, Squamous Cell) : Here we use both an ErbB2 phosphoantibody ( aPY1222 ) and an activation-specific EGFR antibody to show that low concentrations of EGF induce more efficient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGFalpha, while EGFR is more potently activated by TGFalpha